Zavalishin I A, Bochkov N P, Suslina Z A, Zakharova M N, Tarantul V Z, Naroditskiy B S, Suponeva N A, Illarioshkin S N, Shmarov M M, Logunov D Y, Tutyhina I L, Verkhovskaya L V, Sedova E S, Vasiliev A V, Brylev L V, Ginzburg A L
Research Center of Neurology, Russian Academy of Medical Sciences, Russia.
Bull Exp Biol Med. 2008 Apr;145(4):483-6. doi: 10.1007/s10517-008-0124-4.
Two-year experiments were performed to evaluate the neurotrophic effect of hypoxia-inducible factors (vascular endothelial growth factor and angiogenin) expressed in recombinant human adenoviruses in amyotrophic lateral sclerosis. Randomized placebo-controlled trial demonstrated safety and good tolerability of the recombinant antiviral drugs. The life span of patients under conditions of hypoxia increased after treatment with the test drug, which was probably related to improved resistance of motoneurons. The presence of virus-neutralizing antibodies decreases the effectiveness of adenoviral vectors, which necessitates differential approach to the selection of patients and continuous monitoring of gene therapy.
进行了为期两年的实验，以评估重组人腺病毒中表达的缺氧诱导因子（血管内皮生长因子和血管生成素）在肌萎缩侧索硬化症中的神经营养作用。随机安慰剂对照试验证明了重组抗病毒药物的安全性和良好耐受性。用受试药物治疗后，缺氧条件下患者的寿命延长，这可能与运动神经元抵抗力的提高有关。病毒中和抗体的存在会降低腺病毒载体的有效性，这就需要在患者选择上采用差异化方法并持续监测基因治疗。
